Workiva Announces Julie Iskow as Chief Executive Officer
22.2.2023 00:15:00 EET | Business Wire | Press release
Workiva Inc. (NYSE: WK), the company powering transparent reporting for a better world, announced today that Julie Iskow, current President and Chief Operating Officer, has been appointed to succeed Marty Vanderploeg as Chief Executive Officer, effective April 1, 2023. Vanderploeg is stepping down as CEO, but will remain with the company in the role of Non-Executive Chair of the Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230221005356/en/
Workiva Inc. (NYSE: WK) Announces Julie Iskow as Chief Executive Officer (Photo: Business Wire)
Current Board Chair and prospective Lead Independent Director Dave Mulcahy said, “The Board is delighted to appoint Julie Iskow to Chief Executive. She is a strong, respected, and values-driven leader with an impressive and proven track record of delivering consistent high-quality performance through her relentless commitment to our customers and to our people. Julie has played an instrumental role in Workiva’s success over the last three years. She is an engineer, technologist, and strategic operator, whose innovation-first mindset has created a differentiated product offering and sustainable rigor around Workiva’s platform and solutions. The Board is confident in Julie’s ability to lead Workiva through its next stage of growth.”
Of her new role, Iskow said, “Workiva is one of the most relevant and innovative technology companies of our time. We have a transformative platform, unbridled potential, and an enduring foundation on which to build our future. I consider it a distinct privilege to succeed Marty and work with our incredibly talented team to move Workiva’s legacy forward into our next phase of growth and impact.”
Mulcahy said, “We would like to thank Marty for his steadfast leadership. During his tenure, he transformed Workiva into the leading multi-solution platform company for assured integrated business reporting, serving 5,600 customers across the globe. Marty has been an exceptional leader for Workiva, championing an employee culture of progress, product innovation, customer focus, and achieving strong shareholder value. We look forward to working with him in his expanded Board leadership role.”
“As a co-founder of Workiva, I have had the good fortune of working with a talented team for the past 15 years, five of those as CEO,” said Vanderploeg. “Now is the right time for me, and for Workiva, to make this change. Since day one of Julie’s arrival, she’s made our organization better. Julie has spent the past three years thoughtfully building and shaping our remarkable leadership team and operational strategy as we progress toward a long-term goal of $1 billion in revenue. I look forward to supporting her in my new role as Non-Executive Chair.”
About Julie Iskow
Julie Iskow joined Workiva in 2019 as EVP and Chief Operating Officer. She has extensive experience scaling enterprise SaaS companies with strong, profitable growth and has a robust background in product development and optimizing operations. Iskow was promoted to President and Chief Operating Officer in March 2022 and has been overseeing day-to-day operations with global responsibility for technology, product, sales, partners, marketing, services, and customer and partner experience. This transition allows her and the Workiva team to continue with their excellence in execution.
Before joining Workiva, Iskow served as EVP and Chief Technology Officer at Medidata Solutions, creator of cutting-edge SaaS technology and analytics solutions for life sciences. Prior to Medidata, she was the Senior Vice President of Product Development and Chief Information Officer at WageWorks, a SaaS platform for consumer directed benefits solutions. Before WageWorks, she spent over a decade in engineering and technology leadership positions, responsible for automation and robotics software used in high-tech manufacturing.
She currently serves on the board of directors of Workiva Inc. and Five9, a leading provider of cloud software for contact centers. She has a bachelor of science degree from the University of California, Berkeley and a master of science degree from the University of California, Davis.
About Workiva
Workiva Inc. (NYSE:WK) is on a mission to power transparent reporting for a better world. We build and deliver the world’s leading cloud platform for assured integrated reporting to meet stakeholder demands for action, transparency, and disclosure of financial and non-financial data. Workiva offers the only unified SaaS platform that brings customers’ financial reporting, Environmental, Social, and Governance (ESG), and Governance, Risk, and Compliance (GRC) together in a controlled, secure, audit-ready platform. Our platform simplifies the most complex reporting and disclosure challenges by streamlining processes, connecting data and teams, and ensuring consistency. Learn more at workiva.com.
Follow Workiva on LinkedIn: www.linkedin.com/company/workiva
Like Workiva on Facebook: www.facebook.com/workiva
Follow Workiva on Twitter: www.twitter.com/workiva
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005356/en/
Contact information
Investor Inquiries:
Mike Rost
investor@workiva.com
(515) 663-4493
Media Inquiries:
Darcie Brossart
press@workiva.com
(515) 663-4471
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom